

Morten O Holmström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4198457/publications.pdf>

Version: 2024-02-01

34
papers

793
citations

516710

16
h-index

526287

27
g-index

38
all docs

38
docs citations

38
times ranked

999
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. <i>Nature Medicine</i> , 2021, 27, 2212-2223.	30.7	88
2	Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. <i>Seminars in Immunopathology</i> , 2019, 41, 5-19.	6.1	71
3	The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. <i>Leukemia</i> , 2016, 30, 2413-2416.	7.2	60
4	The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. <i>Leukemia</i> , 2017, 31, 495-498.	7.2	51
5	Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish myeloma database. <i>American Journal of Hematology</i> , 2015, 90, E73-4.	4.1	44
6	JAK2V617F but not CALR mutations confer increased molecular responses to interferon- α via JAK1/STAT1 activation. <i>Leukemia</i> , 2019, 33, 995-1010.	7.2	43
7	The Danish National Multiple Myeloma Registry. <i>Clinical Epidemiology</i> , 2016, Volume 8, 583-587.	3.0	38
8	Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. <i>PLoS ONE</i> , 2016, 11, e0165336.	2.5	38
9	The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. <i>OncImmunology</i> , 2018, 7, e1390641.	4.6	33
10	Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. <i>OncImmunology</i> , 2018, 7, e1433521.	4.6	30
11	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 637420.	2.8	29
12	Frequent adaptive immune responses against arginase-1. <i>OncImmunology</i> , 2018, 7, e1404215.	4.6	27
13	High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. <i>Blood Cancer Journal</i> , 2019, 9, 8.	6.2	27
14	Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. <i>Frontiers in Immunology</i> , 2018, 9, 2264.	4.8	19
15	The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. <i>OncImmunology</i> , 2020, 9, 1771142.	4.6	18
16	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1763.	3.7	17
17	Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 125-128.	1.3	16
18	Cancer immune therapy for myeloid malignancies: present and future. <i>Seminars in Immunopathology</i> , 2019, 41, 97-109.	6.1	16

#	ARTICLE	IF	CITATIONS
19	Sorted peripheral blood cells identify <i>CALR</i> mutations in B- and T-lymphocytes. <i>Leukemia and Lymphoma</i> , 2018, 59, 973-977.	1.3	15
20	Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. <i>Oncolimmunology</i> , 2018, 7, e1468957.	4.6	15
21	Cancer immune therapy for lymphoid malignancies: recent advances. <i>Seminars in Immunopathology</i> , 2019, 41, 111-124.	6.1	15
22	Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 315-324.	4.2	12
23	The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy. <i>Oncolimmunology</i> , 2017, 6, e1358334.	4.6	10
24	Cytotoxic T cells isolated from healthy donors and cancer patients kill TGF β -expressing cancer cells in a TGF β -dependent manner. <i>Cellular and Molecular Immunology</i> , 2021, 18, 415-426.	10.5	10
25	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	10
26	Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens. <i>Cancers</i> , 2020, 12, 3045.	3.7	9
27	Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment. <i>Oncolimmunology</i> , 2022, 11, 2026020.	4.6	9
28	Genetic variants in the <i>P2RX7</i> gene are associated with risk of multiple myeloma. <i>European Journal of Haematology</i> , 2014, 93, 172-174.	2.2	7
29	An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma. <i>Oncolimmunology</i> , 2021, 10, .	4.6	5
30	Characterization of TGF β -specific CD4 ⁺ T cells through the modulation of TGF β expression in malignant myeloid cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2575-2577.	10.5	5
31	Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3296-3299.	1.3	2
32	Neo-antigen specific memory T-cell responses in healthy individuals. <i>Oncolimmunology</i> , 2019, 8, e1599640.	4.6	2
33	A Heterogeneous Response Pattern to Interferon-alpha2 with Induction of a Significant Decrease in the Calreticulin Mutant Allele Burden in a Subset of Patients with Essential Thrombocythemia and Primary Myelofibrosis. <i>Blood</i> , 2015, 126, 4057-4057.	1.4	0
34	Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	0